On the afternoon of April 8, 2026, Wang Bangjin, Director of the Standing Committee of the Jiangbei District People's Congress of Ningbo, and his delegation visited Zhejiang Tianyuan Biotechnology Co., Ltd. for inspection and guidance. Huang Bisheng, Chairman of the Group, Zhu Youwu, Chief Administrative Officer, and Jiao Mingming, General Manager of the company, warmly received the visiting leaders.

      Director Wang Bangjin and his delegation first toured the company's science and technology exhibition hall, gaining a detailed understanding of Tianyuan Biotechnology's development history, business layout, core technologies, and outstanding achievements in the field of cell research. In the exhibition hall, "national-level" qualifications and certifications—such as the National Stem Cell Translational Resource Bank and the status of being a formulating unit for the group standard on immune function assessment methods under the National Health Commission—highlighted the company's leading position in the industry.

      The leaders then entered the laboratory to inspect the research environment and hardware facilities on site. In the laboratory, Director Wang Bangjin held an in-depth exchange with Dr. Chen Junjie, the company's Chief Technology Officer, focusing on a report of the latest innovative achievements in iPS cell (induced pluripotent stem cell) technology, including key technical indicators such as cardiomyocyte differentiation, the preparation of sinoatrial node organoids (biological pacemakers), and a cell cryopreservation and recovery rate of over 90%, as well as the latest progress of the product pipeline entering the large animal testing stage. Director Wang Bangjin expressed high affirmation of the company's dedicated and meticulous work in the field of cutting-edge biotechnology.

      At the symposium, Director Wang Bangjin noted that Tianyuan Biotechnology, as a representative enterprise of the biopharmaceutical industry in Jiangbei District, has played a pioneering and leading role in technological innovation and industrialization of cell therapy, making positive contributions to regional economic development and the national health cause. Chairman Huang Bisheng introduced that the company is actively laying out its presence in Hainan's pilot zone to promote the application of technology translation, while deepening industry-academia-research cooperation with institutions such as Ningbo University and the Institute of Science and Technology of the National Health Commission. The company aims to achieve clinical approval and large-scale production of cell therapy drugs during the "15th Five-Year Plan" period, contributing more "Tianyuan strength" to the cause of human health.

      This inspection and guidance activity fully reflects the high importance and earnest expectations that Jiangbei District leaders attach to Tianyuan Biotechnology's development. Tianyuan Biotechnology will take this as motivation to continue increasing R&D investment, strengthening technological innovation, and promoting the translation of scientific research achievements, injecting strong momentum into the high-quality development of the biopharmaceutical industry in Jiangbei District and Ningbo as a whole.

      Founded in 2017, Zhejiang Tianyuan Biotechnology Co., Ltd. is a national high-tech enterprise dedicated to the integrated development of cell R&D, production, operations, and services. It holds valuable resource banks including an HLA umbilical cord matching bank, an iPS seed cell bank, and a tumor cell bank, and serves as a formulating unit for the group standard on immune function assessment methods under the National Health Commission. The company has jointly established a Metabolic and Immune Monitoring Joint Laboratory with the Institute of Science and Technology of the National Health Commission, and also serves as the Ningbo Storage Center of the National Stem Cell Translational Resource Bank and the Achievement Translation Center of the Institute of Science and Technology of the National Health Commission, among other important research and service platforms.